Chandan HealthcareShare price, financial results, shareholding and management

NSE Emerge · CHANDANDiagnostic centresListed 17 Feb 2025IPO ₹159Catch them young
chandandiagnostic.com ↗Live price on NSE ↗ISIN INE0B2N01016 · Lot 800 shares · ₹1.96 lakh
₹245.00
+2.80% on the day
Close · 19 Nov 2026
Valuation
Market cap
₹630 cr
Stock P/E
23.3peers 21.4
Book value
₹66.1
Price to book
3.71
EV / operating profit
12.9
Market cap to sales
2.28
Returns and growth
ROCE · FY26
22.4%
ROE · FY26
18.5%
ROE, 3-year average
30.9%
Operating margin · FY26
19.0%peers 24.5%
Sales growth, 3 years
26.4%
Profit growth, 3 years
108.2%
Safety
Debt to equity
0.32peers 0.23
Borrowings
₹53.8 cr
Interest cover
7.5×
Cash from business / op. profit
31%
Debtor days
114
Pledged
0.00%
Ownership and share
Promoter holding
47.20%
Change in promoter holding
-2.41 pts
Shareholders
1,685
52-week high / low
₹352 / ₹185
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Chandan Healthcare share price chart

₹245.00-29.44% 1 year

Close on 19 Nov 2026 · +2.81% on the day · Vol 32,000

Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 19 Nov 2026

1 month
+7.2%
3 months
+4.0%
6 months
+4.2%
1 year
-29.4%
Since IPO
+54.1%
Traded a day, 20 days
₹0.54 cr
Taken for delivery
72%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+20%+22%
3 years, a year+26%+108%
Latest half, H2 FY26+17%-1%

About Chandan Healthcare: business, products and customers

Chandan Healthcare runs diagnostic centres and laboratories that do blood tests and medical scans for patients, hospitals, companies and state governments. It began in Lucknow, now works across many states of India, and its shares trade on NSE Emerge.

Chandan Healthcare does pathology (blood and other laboratory tests) and radiology (X-ray, ultrasound, CT and MRI scans) through its own centres, standalone laboratories and collection points. Samples go to central reference laboratories at Lucknow in Uttar Pradesh and Haldwani in Uttarakhand, and the first centre opened in Lucknow in 1991, before the company was formed in 2003. At 31 March 2026 Uttar Pradesh held 173 of its 313 centres and laboratories, and the company did over 88 lakh tests in FY26.

The company serves three groups: patients who walk in or book a home collection, hospitals, insurers and companies, and state governments that hire it to run scans and tests inside public hospitals. In the June 2026 quarter, standalone sales came 38% from patients, 32% from institutions and 30% from governments. The company said on its August 2026 call that government bills take about four months on average to be paid.

Read more about the business

During FY26 the company opened its first centres in cities such as Mumbai, Kolkata, Bengaluru, Chandigarh, Raipur and Vadodara, and has started franchise collection centres run by local sample collectors who pay for their own set up. It is also the exclusive diagnostics partner of Jeena Sikho Lifecare hospitals and clinics for five years. In August 2026 it divested its 53.56% stake in Chandan Pharmacy, its retail pharmacy arm, to group company Chandan Hospital, so that pharmacy revenue stops counting from 1 September 2026.

From the offer document, the FY26 annual report, the February 2026 press release and the June and August 2026 earnings calls.

Read the deeper study ↓

In its favour

  • Sales have grown fast: 26% a year over three years.
  • It earns a high return on the money it uses: ROCE 22% in FY26.

To watch

  • Eight comprehensive diagnostic centres the company said would open within three to four months of its August 2026 call (Earnings call, August 2026, p.5).
  • PET scan machines at Kanpur and Gorakhpur, first put in the June 2026 quarter and now due two to three months after August 2026 (Earnings call, June 2026, p.6; August 2026, p.5).
  • Government radiology centres: eight in Punjab and the Guwahati centre due within about three months of August 2026 (Earnings call, August 2026, p.7).
  • Pharmacy revenue leaving the accounts from 1 September 2026 after the Chandan Pharmacy stake went to Chandan Hospital (Earnings call, August 2026, p.13 and p.15).
  • Customers take longer to pay than before: 114 days in FY26, against 54 in FY20.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Chandan Healthcare revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown fast. Last year profit grew roughly in step with sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
-1000100200300Sales, FY20: 67 ₹ cr67Net profit, FY20: 1 ₹ cr1FY20Sales, FY21: 56 ₹ cr56Net profit, FY21: 1 ₹ cr1FY21Sales, FY22: 120 ₹ cr120Net profit, FY22: -1 ₹ cr-1FY22Sales, FY23: 137 ₹ cr137Net profit, FY23: 3 ₹ cr3FY23Sales, FY24: 177 ₹ cr177Net profit, FY24: 16 ₹ cr16FY24Sales, FY25: 230 ₹ cr230Net profit, FY25: 22.2 ₹ cr22.2FY25Sales, FY26: 276 ₹ cr276Net profit, FY26: 27.1 ₹ cr27.1FY26
The latest halves, ₹ crore
SalesNet profit
050100150Sales, H2FY25: 120 ₹ cr120Net profit, H2FY25: 11.5 ₹ cr11.5H2FY25Sales, H1FY26: 136 ₹ cr136Net profit, H1FY26: 15.6 ₹ cr15.6H1FY26Sales, H2FY26: 141 ₹ cr141Net profit, H2FY26: 11.5 ₹ cr11.5H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.

Chandan Healthcare half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H2FY25H1FY26H2FY26
Sales119.66135.80140.59
Expenses98.17107.51116.32
Operating profit21.4928.2924.27
OPM18.0%20.8%17.3%
Interest2.382.803.08
Depreciation3.514.934.85
Profit before tax16.6722.2616.01
Net profit11.5315.6011.46

Chandan Healthcare profit and loss

Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Sales6756120137177230.12276.39
Expenses6051117128150188.79223.83
Operating profit65292641.3352.57
OPM9.0%9.0%1.9%7.0%15.0%18.0%19.0%
Other income000012.054.28
Interest222234.585.88
Depreciation222236.749.78
Exceptional and other items··1···-2.92
Profit before tax21-152132.0638.27
Tax rate50.0%0.0%3.0%40.0%23.8%30.8%29.3%
Net profit11-131622.1727.06
EPS ₹0.710.41-0.561.688.1410.7811.07
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%

The years to FY24 come rounded to the nearest crore in the source.

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

Chandan Healthcare profitability

Margins and returns on capital

Last year the company kept about as much from each rupee of sales as the year before. It earns a high return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%10%20%30%FY20: 9.0%9.0%FY20FY21: 9.0%9.0%FY21FY22: 1.9%1.9%FY22FY23: 7.0%7.0%FY23FY24: 15.0%15.0%FY24FY25: 18.0%18.0%FY25FY26: 19.0%19.0%FY26
Per cent
FY20FY21FY22FY23FY24FY25FY26
Operating margin9.0%9.0%1.9%7.0%15.0%18.0%19.0%
Tax rate50.0%0.0%3.0%40.0%23.8%30.8%29.3%
ROCE·7.7%2.5%15.7%38.4%29.6%22.4%
ROE·4.1%-4.1%11.8%47.1%27.1%18.5%
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Chandan Healthcare debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
050100150200Net worth, FY20: 24 ₹ cr24Borrowings, FY20: 15 ₹ cr15FY20Net worth, FY21: 25 ₹ cr25Borrowings, FY21: 14 ₹ cr14FY21Net worth, FY22: 24 ₹ cr24Borrowings, FY22: 17 ₹ cr17FY22Net worth, FY23: 27 ₹ cr27Borrowings, FY23: 21 ₹ cr21FY23Net worth, FY24: 41 ₹ cr41Borrowings, FY24: 36 ₹ cr36FY24Net worth, FY25: 123 ₹ cr123Borrowings, FY25: 48.2 ₹ cr48.2FY25Net worth, FY26: 170 ₹ cr170Borrowings, FY26: 53.8 ₹ cr53.8FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-40-2002040Net profit, FY20: 1 ₹ cr1FY20Cash from the business, FY21: -7 ₹ cr-7Net profit, FY21: 1 ₹ cr1FY21Cash from the business, FY22: 6 ₹ cr6Net profit, FY22: -1 ₹ cr-1FY22Cash from the business, FY23: 4 ₹ cr4Net profit, FY23: 3 ₹ cr3FY23Cash from the business, FY24: 1 ₹ cr1Net profit, FY24: 16 ₹ cr16FY24Cash from the business, FY25: -29.1 ₹ cr-29.1Net profit, FY25: 22.2 ₹ cr22.2FY25Cash from the business, FY26: 16.2 ₹ cr16.2Net profit, FY26: 27.1 ₹ cr27.1FY26

Bars below the line are cash going out.

Chandan Healthcare balance sheet

At each 31 March · ₹ crore

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Equity capital202020202024.4524.45
Reserves45472198.15145.43
Net worth2425242741122.60169.88
Borrowings151417213648.1653.75
Other liabilities201741504139.8665.89
Total liabilities59568298118210.62289.52
Fixed assets202029334876.35101.24
Capital work in progress00000412
Investments20116731.1519.96
Other assets1925475867129.12156.32
Receivables·····46.7086.40
Inventory·····31.3733.74
Cash·····6.213.58
Trade payables·····25.7840.90

Chandan Healthcare cash flow

₹ crore

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Cash from operations·-7641-29.0516.17
Cash from investing·7-11-6-15-35.75-39.90
Cash from financing·0321667.1121.10
Net cash flow·0-2022.31-2.63
Capital spending·····38.7042.56

Working capital

Days

Days
FY20FY21FY22FY23FY24FY25FY26
Debtor days547688635974114
Inventory days8878467196126112
Days payable126224185251102103135
Cash conversion cycle15-69-51-117539892
Working capital days-66-10-11-21-15095

Chandan Healthcare peers and competitors

Listed SME companies in the same industry

By sales, Chandan Healthcare is number 1 of the 23 listed SME companies in healthcare services.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Chandan Healthcare63023.327627.119.0%0.32
Asarfi Hospital36421.41591722.0%0.59
Unihealth Hospitals94336.513225.840.8%0.15
Sangani Hospitals8829.410737.6%0.04
Hannah Joseph Hospital23621.5921127.0%0.28
Star Imaging And Path Lab1337.0891937.0%0.18
Nephro Care India14141.988.73.49.4%0.00
Modern Diagnostic & Research Centre9518.183.15.315.4%0.63
Pramodini Medicare25415.0621750.0%0.34
Adeshwar Meditex--56.11.34.9%0.16
ABH Healthcare529.351.65.628.8%3.17
Median of the 10 others14121.488.98.324.5%0.23

Chandan Healthcare shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own less than half the company, a little less than in the first filing shown. Foreign and Indian funds own a noticeable share. The number of shareholders has come down.

Promoters
47.20%
-2.00 pts since Feb 25
Foreign investors (FIIs)
0.01%
at Jun 26; not in the latest pattern
Indian institutions (DIIs)
6.49%
+1.14 pts since Feb 25
HNIs (over ₹2 lakh each)
28.18%
+5.92 pts since Feb 25
Small holders (up to ₹2 lakh)
9.64%
-0.48 pts since Feb 25
Companies and others
8.49%
+1.90 pts since Feb 25
Number of shareholders
1,685
3,099 in Feb 25

Chandan Healthcare shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Feb 25Mar 25Sep 25Dec 25Mar 26Jun 26Sep 26
Promoters49.20%49.43%49.47%49.47%49.55%49.61%47.20%
Foreign investors (FIIs)6.48%3.86%1.11%-0.01%0.01%-
Indian institutions (DIIs)5.35%6.70%5.02%4.76%5.03%5.09%6.49%
HNIs (over ₹2 lakh each)22.26%28.63%29.99%31.23%29.98%29.66%28.18%
Small holders (up to ₹2 lakh)10.12%4.38%7.08%8.70%9.52%9.45%9.64%
Companies and others6.59%7.00%7.33%5.84%5.91%6.18%8.49%
Number of shareholders3,0999401,3071,4641,6241,5911,685

The named holders are at 30 Sept 2026, beside 14 Sept 2026, each under the group the pattern files them in.

Chandan Healthcare study: the business from its own documents

Read from 14 of the company's own documents

Chandan Healthcare so far

From the company's own record

  1. September 2003Company formed
  2. 17 Feb 2025Listed on NSE Emerge at ₹159
  3. 30 Sept 2026Promoters at 47.20%
  4. 19 Nov 2025Highest close since listing, ₹333.86

Chandan Healthcare key facts from the filings

Each figure with the document it comes from

Network
327 centres
Own centres, laboratories and franchise centres together at the August 2026 call, in 15 states.Earnings call, August 2026, p.3 and p.5
Franchise centres
375
Collection franchises opened in about four months; the company says it aims for 1,000 this financial year.Earnings call, August 2026, p.4 and p.5
Pharmacy share of FY26 revenue
43.5%
Share of consolidated revenue from the retail pharmacy business, which earned a much thinner margin than diagnostics.Annual report FY26, p.69 and p.70
Pharmacy stake sold
₹16.8 cr
Price for the 53.56% stake in Chandan Pharmacy, sold to group company Chandan Hospital; its revenue leaves the books from 1 September 2026.Earnings call, August 2026, p.4, p.13 and p.15
Government contracts
10 contracts
Ten year radiology contracts won in FY26 in Punjab, Haryana and Assam; the company puts their combined value at about ₹800 cr over ten years.Annual report FY26, p.68; earnings call, June 2026, p.5
Show 4 more facts
Jeena Sikho partnership
₹1.5 cr a month
Monthly business from the exclusive five year diagnostics deal with Jeena Sikho hospitals and clinics, with about 80% of their centres covered.Earnings call, August 2026, p.21; press release, February 2026, p.2
Warrants issued
₹104.1 cr
Up to this amount from 44,50,000 warrants at ₹234 each, allotted in February 2026 to the promoter group and investors including Jeena Sikho Lifecare; a quarter had been paid in by June 2026.Annual report FY26, p.34; press release, February 2026, p.3; earnings call, June 2026, p.10
Accredited laboratories
8 → 16
Laboratories with NABL accreditation, at the IPO and at 31 March 2026; six radiology centres also hold NABH accreditation.Offer document, p.168; annual report FY26, p.68
Board or management change
Resignation
On 6 October 2026 the company disclosed the resignation of a director, key managerial person or senior manager; the subject line, all that was available, does not name who.Announcement, 6 Oct 2026

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

On its August 2026 call the company said it aims for 1,000 franchise centres this financial year and 3,000 within two years, and plans to open eight comprehensive diagnostic centres in the next three to four months, two PET scan machines at Kanpur and Gorakhpur in two to three months and a genome laboratory at Lucknow in about six months. Amar Singh, Chairman and Managing Director, said on that call that diagnostics revenue is expected to grow by more than half each year for three years; these are the company's own statements, not newboard's.

375Franchise centresAugust 2026 call
₹800 crGovernment contracts, company estimateOver ten years, June 2026 call
1,000Franchise centres aimed forThis financial year, company says
What management saidWhenWhat happened
1,000 franchise centres in three yearsDec 2025 presentation, p.25375 open by August 2026; the aim moved to this financial year (August 2026 call, p.4)
Two PET scan machines to start in the first quarter of FY27Jun 2026 call, p.6Not yet running at the August 2026 call; now due in two to three months (August 2026 call, p.5)
Genome laboratory at Lucknow planned in the first half of FY27Feb 2026 call, p.4Slated to open in about six months, the company said in August 2026 (August 2026 call, p.5)

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

Chandan Healthcare earns money from blood tests and scans done for patients, hospitals, companies and state governments, and diagnostics earns far more on each rupee than the pharmacy it has now let go.

Its weak spots are money owed by government hospitals, which comes in slowly, and the cash it needs to open many new centres at once.

AverageCan it set its own prices?Routine blood tests are a crowded market where prices keep getting pushed down, the company says. Scans bring in much more for each test.
The evidence. The annual report lists intense price competition in routine pathology as a threat; FY26 revenue per test was ₹142 in pathology and ₹909 in radiology.Annual report FY26, p.67 and p.69
AverageHow strong is it against rivals?It is well rooted in Uttar Pradesh and Uttarakhand with accredited labs, but in the new cities it meets national chains, hospital labs and online rivals.
The evidence. Uttar Pradesh holds 173 of its 313 centres and labs; it has 16 NABL accredited labs; the company names regional labs, hospital departments and digital aggregators as competitors.Annual report FY26, p.67 to p.69
WatchWho are its customers?A few large accounts have mattered a lot, and government hospitals bring close to a third of standalone sales. The company says it keeps government work below a set share because of slow payments.
The evidence. The two largest customers gave 50.5% of revenue in the nine months to December 2024; in the June 2026 quarter standalone sales were 38% patients, 32% institutions and 30% government, and the company does not want government above 40%.Offer document, p.171; earnings call, August 2026, p.6 and p.17
WatchDoes it need a lot of money?Yes. Each full centre with MRI and CT costs several crore, and the company is opening many at once while waiting months for government payments.
The evidence. A comprehensive centre costs about ₹6 cr to ₹7 cr and a lab about ₹1 cr; planned FY27 spending was ₹45 cr to ₹50 cr; up to ₹104.1 cr was raised through warrants.Earnings call, June 2026, p.7 and p.20; annual report FY26, p.34
StrongCan it keep finding new work?New work has come from several directions in the past year: government hospitals, a hospital chain partner and franchise collection centres.
The evidence. Ten government radiology contracts won in FY26, an exclusive five year deal with Jeena Sikho Lifecare, and 375 franchise centres by August 2026.Annual report FY26, p.68; earnings call, August 2026, p.4
AverageDo good and bad years swing a lot?People need tests in every year, but the company says some months are slower, and its margins were very thin only a few years ago.
The evidence. EBITDA margin was 1.80% in FY22, 6.77% in FY23 and 14.78% in FY24; on the August 2026 call the company called it a seasonal business.Offer document, p.169; earnings call, August 2026, p.18

Who runs Chandan Healthcare?

Promoters, directors and officers; tap a name for the background

ASAmar SinghPromoter, Chairman and Managing Director · holds 9.38%

Holds a Bachelor of Medicine and Bachelor of Surgery degree and has over two decades of experience in healthcare. Associated with the company since its start and re-designated Managing Director on 30 March 2024; oversees operations and strategy. On the August 2026 call Amar Singh described being the founder of the Chandan Group and said the Chandan name comes from Chandan Singh, the father of Amar Singh.

Offer document, p.205; earnings call, August 2026, p.22
ASAsmita SinghPromoter and Managing Director

Holds a Bachelor of Business Administration and a Master of Business degree, with over two decades of experience in marketing. Associated with the company since its start, re-designated Managing Director on 30 March 2024, and oversees operations and marketing. The offer document states that Amar Singh is the father of Asmita Singh.

Offer document, p.205 and p.206
VLVinay LambaPromoter and Non-Executive Director · holds 6.33%

Trained at the Marine Engineering and Research Institute, Calcutta, and holds a certificate of competency as Marine Engineer Officer Class I. Operations head at Indra Diagnostic Centre and Blood Bank Limited from 1999 to 2003; works on equipment calibration standards and procurement at the company. A director since 2003, re-designated Non-Executive Director on 1 July 2024.

Offer document, p.204 and p.206
VSVijay SinghPromoter and Head (Information Technology) · holds 3.59%

Holds a Bachelor of Arts and a Post Graduate Diploma in Computer Engineering. Head of Information Technology at the company since 2003, responsible for the software the company runs on, with more than twenty years of experience in information technology.

Offer document, p.218 and p.221
SSShaleen SolankiPromoter · holds 3.59%

Holds a Bachelor of Science degree from Kumaun University and a Post Graduate Diploma in Business Management from the Institute of Productivity and Management.

Offer document, p.221
ASAlok SinghPromoter · holds 1.20%

Holds a Bachelor of Technology (Information Technology) from Amity University and a Master of Business Administration from the Indian Institute of Technology, Madras. Project Engineer at Wipro Technologies from 2016 to 2018, and associated with Chandan Hospitals Limited since 2018.

Offer document, p.221
AHAmaranita Holdings (India) Private LimitedCorporate promoter · holds 16.60%

An investment company incorporated on 14 May 2008 in Lucknow. At the offer document, Amar Singh held 73.66% of it and Asmita Singh 9.64%, with the rest held by Anita Singh, Anant Singh and Aasti Singh.

Offer document, p.222
RNRajeev NainChief Financial Officer and Company Secretary

Cleared the final examination of the Institute of Chartered Accountants of India, is an associate member of the Institute of Company Secretaries of India, and completed a Private Equity and Capital Market Financing programme at the Indian Institute of Management, Bangalore. In the role since 28 July 2014.

Offer document, p.217
VJVinod JainIndependent Director

Holds a Master of Surgery (General Surgery) and fellowships from the American College of Surgeons and the International College of Surgeons. Professor at King George Medical University, Lucknow, from 1998 until retiring in October 2022; on the board since 13 August 2024.

Offer document, p.206
AGAmit GuptaIndependent Director

Holds a Bachelor of Science degree, is a fellow member of the Institute of Company Secretaries of India and holds a Diploma in Business Finance; over two decades of experience in compliance and secretarial work. On the board since 13 August 2024 and chairs the audit committee.

Offer document, p.206; annual report FY26, p.30

Chandan Healthcare latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹141 cr (+17%), net profit ₹11.5 cr (-1%) on H2 FY25.
  • Shareholding, 30 Sept 2026: promoters 49.61% to 47.20%; Negen Undiscovered Value Fund no longer named at 1% or more (was 3.09%).

Chandan Healthcare annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Chandan Healthcare share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Chandan Healthcare's data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (2,57,02,062 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • ✓Earnings per share moves in line with profit across the years shown.
  • ✓Revenue and profit are reported for every year shown, FY20 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Chandan Healthcare

What does Chandan Healthcare do?

Chandan Healthcare runs diagnostic centres and laboratories that do blood tests and medical scans for patients, hospitals, companies and state governments. It began in Lucknow, now works across many states of India, and its shares trade on NSE Emerge.

What is the share price of Chandan Healthcare?

₹245 at the close on 19 Nov 2026, from the exchange's daily figures.

What is the market cap of Chandan Healthcare?

₹630 cr at the close on 19 Nov 2026, on 2,57,02,062 shares.

What is the P/E of Chandan Healthcare?

23.3 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).

What are Chandan Healthcare's revenue and profit?

Revenue ₹276 cr and profit after tax ₹27 cr in FY26.

Who are the promoters of Chandan Healthcare?

Amar Singh, Asmita Singh, Vinay Lamba, Vijay Singh, Shaleen Solanki, Alok Singh, Amaranita Holdings (India) Private Limited; promoters held 47.20% at 30 Sept 2026.

What was the IPO price of Chandan Healthcare?

₹159 a share; it listed on 17 Feb 2025.

What is Chandan Healthcare's website?

www.chandandiagnostic.com

More SME companies like Chandan Healthcare

Other listed SME companies in healthcare services, the closest in size first, each read from its own documents.

Every listed SME company in Healthcare Services → · SME companies listed in 2025 →

Built from 3 earnings call transcripts, 3 investor presentations, 2 annual reports, 2 credit rating notes, 2 press releases, 1 offer document, 1 result filing, 173 exchange announcements, 7 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.